
    
      This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and
      investigator-blind, placebo-controlled, randomized, 3-period, crossover study. Part 1 will
      assess the safety and tolerability of LY2886721 single doses, how the body handles the drug,
      and the drug's effect on the body. Part 2 is a subject- and investigator-blind,
      placebo-controlled, randomized study to assess the safety and tolerability of an LY2886721
      single dose, how the body handles the drug, and the drug's effect on the body including in
      cerebrospinal fluid.
    
  